Key result
In female patients with chronic fatigue syndrome/myalgic encephalomyelitis, reduced heart rate variability parameters were significantly associated with increased self-reported fatigue severity.
Why the study?
People with CFS/ME tend to have lower HRV, but few previous studies have evaluated its association with illness-related complaints, with most being inconclusive.
Do heart rate variability parameters correlate with self-reported fatigue severity in female patients with chronic fatigue syndrome/myalgic encephalomyelitis?
Case-Control (n=70)
No
Do heart rate variability parameters correlate with self-reported fatigue severity in female patients with chronic fatigue syndrome/myalgic encephalomyelitis?
Answers are grounded in this paper and cite their sources.
No immediate change to CFS/ME care; hypothesis-generating for HRV as fatigue correlate needing prospective validation.
BACKGROUND: Heart rate variability (HRV) is an objective, non-invasive tool to assessing autonomic dysfunction in chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). People with CFS/ME tend to have lower HRV; however, in the literature there are only a few previous studies (most of them inconclusive) on their association with illness-related complaints. To address this issue, we assessed the value of different diurnal HRV parameters as potential biomarker in CFS/ME and also investigated the relationship between these HRV indices and self-reported symptoms in individuals with CFS/ME. METHODS: In this case-control study, 45 female patients who met the 1994 CDC/Fukuda definition for CFS/ME and 25 age- and gender-matched healthy controls underwent HRV recording-resting state tests. The intervals between consecutive heartbeats (RR) were continuously recorded over three 5-min periods. Time- and frequency-domain analyses were applied to estimate HRV variables. Demographic and clinical features, and self-reported symptom measures were also recorded. RESULTS: CFS/ME patients showed significantly higher scores in all symptom questionnaires (p < 0.001), decreased RR intervals (p < 0.01), and decreased HRV time- and frequency-domain parameters (p < 0.005), except for the LF/HF ratio than in the healthy controls. Overall, the correlation analysis reached significant associations between the questionnaires scores and HRV time- and frequency-domain measurements (p < 0.05). Furthermore, separate linear regression analyses showed significant relationships between self-reported fatigue symptoms and mean RR (p = 0.005), RMSSD (p = 0.0268) and HFnu indices (p = 0.0067) in CFS/ME patients, but not in healthy controls. CONCLUSIONS: Our findings suggest that ANS dysfunction presenting as increased sympathetic hyperactivity may contribute to fatigue severity in individuals with ME/CFS. Further studies comparing short- and long-term HRV recording and self-reported outcome measures with previous studies in larger CFS/ME cohorts are urgently warranted.
No takes yet. Share an insight, caveat, or question.
Escorihuela et al. (2020) conducted a case-control in Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) (n=70). Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) vs. Healthy controls was evaluated on Heart rate variability time- and frequency-domain parameters and their correlation with fatigue severity (p=<0.005). In female patients with chronic fatigue syndrome/myalgic encephalomyelitis, reduced heart rate variability parameters were significantly associated with increased self-reported fatigue severity.
Synapse has enriched 10 related papers. Consider them for comparative context: